Cargando…

842. Impact of Active Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections in US Hospitals Between 2014 and 2019

BACKGROUND: Treatment choices for carbapenem-resistant (CR) Acinetobacter baumannii infections are limited. We analyzed the impact of active treatment on outcomes in patients infected with CR vs carbapenem-susceptible (CS) A. baumannii. METHODS: Adult patients hospitalized between January 1, 2014 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pogue, Jason M, Zhou, Yun, Kanakamedala, Hemanth, Cai, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776630/ http://dx.doi.org/10.1093/ofid/ofaa439.1031

Ejemplares similares

551. Burden of Illness in Carbapenem-Resistant Acinetobacter baumannii Infections in US Hospitals (2014 to 2018)
por: Pogue, Jason M, et al.
Publicado: (2019)

Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019
por: Pogue, Jason M., et al.
Publicado: (2022)

848. Trends of Carbapenem Resistance in Enterobacterales in the US Between 2015 and 2019
por: Marcella, Stephen, et al.
Publicado: (2020)

1458. Burden of Illness in Patients with Urinary Tract Infections With or Without Bacteremia Caused by Carbapenem-Resistant Gram-Negative Pathogens in US Hospitals (2014 to 2018)
por: Shields, Ryan K, et al.
Publicado: (2019)

1490. Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex - A Retrospective Review
por: Rana, Khurram, et al.
Publicado: (2020)

154. comparative Genomics Reveals Extra-hospital Transmission Networks of Carbapenem-resistant acinetobacter Baumannii sustained over Multiple Years in a US Midwest City
por: Calix, Juan J, et al.
Publicado: (2020)

Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia
por: Shields, Ryan K., et al.
Publicado: (2021)

2158. An outbreak of carbapenem-resistant Acinetobacter baumannii at a tertiary hospital in Ethiopia
por: Adbaru, Mulatu G, et al.
Publicado: (2023)

813. The Reduction of the acquisition rate of carbapenem resistant Acinetobacter baumannii after room privatization in the intensive care unit
por: Jung, Jongtak, et al.
Publicado: (2020)

548. Carbapenem-Resistant Acinetobacter baumannii Antibiotic Susceptibility Testing and Antibiogram Formation, Connecticut 2017–2019
por: Paranandi, Anu, et al.
Publicado: (2019)

164. Analysis of Adult, Hospitalized Patients With Carbapenem-resistant (CR) Gram-Negative Bloodstream Infections (GN-BSIs) due to Lactose Fermenters (LFs) and Non-lactose Fermenters (NLFs): Is There a Difference in Outcomes?
por: Lodise, Thomas, et al.
Publicado: (2019)

Characterization of carbapenem-resistant Acinetobacter baumannii strains isolated from hospitalized patients in Palestine
por: Handal, R, et al.
Publicado: (2015)

597. False Positive Carbapenemase Test in Carbapenem Resistant Acinetobacter baumannii
por: Tao, Lili, et al.
Publicado: (2023)

1855. Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia
por: Lee, Chan Mi, et al.
Publicado: (2022)

Outbreak of carbapenem-resistent Acinetobacter baumannii (CRAB) in a surgical department of a university hospital
por: Messler, S, et al.
Publicado: (2011)

Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
por: Iovleva, Alina, et al.
Publicado: (2022)

636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States
por: Iovleva, Alina, et al.
Publicado: (2019)

1447. Cluster of Carbapenem-resistant Acinetobacter baumannii in the Context of Local Community Transmission
por: Darwish, Malik, et al.
Publicado: (2023)

Carbapenem-resistant Acinetobacter baumannii outbreak at university hospital
por: Takagi, E.H., et al.
Publicado: (2009)

523. Dual vs. Triple Antibiotic Therapy for Carbapenem-Resistant Acinetobacter baumannii Infections
por: Markelwith, Justin Patrick, et al.
Publicado: (2019)

2557. Development of Rabbit Models of Ventilator-Associated Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Petraitis, Vidmantas, et al.
Publicado: (2023)

2759. Cefiderocol vs Best Available Therapy for the Treatment of Carbapenem- Resistant Acinetobacter baumannii
por: Daisey, Gabrielle N, et al.
Publicado: (2023)

2477. Characteristics of patients infected with Carbapenem-resistant Acinetobacter baumannii complex and Carbapenem-resistant Enterobacterales in Tennessee, 2016–2021
por: Patel, Dipen, et al.
Publicado: (2023)

2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022
por: Bulens, Sandra N, et al.
Publicado: (2023)

Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012–2015
por: Bulens, Sandra N., et al.
Publicado: (2018)

645. Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014-2021
por: Shortridge, Dee, et al.
Publicado: (2022)

554. Association of emr and mdt Genes in Carbapenem Resistant Acinetobacter baumannii with Clinical Outcome in A Tertiary Care Hospital
por: CHAUDHARY, M O N I K A, et al.
Publicado: (2023)

2137. Real World Experience with Eravacycline for the Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
por: Lim, Andy, et al.
Publicado: (2023)

216. Association Between Days to Initiate Appropriate Therapy and Hospital Length of Stay Among Adult Hospitalized Patients With Gram-negative Bloodstream Infections (GN-BSI)
por: Lodise, Thomas, et al.
Publicado: (2019)

158. Intra- and Inter-hospital Epidemiology of Carbapenem-resistant klebsiella Pneumoniae in US Hospitals
por: Luterbach, Courtney, et al.
Publicado: (2020)

Is Aerosalization a Problem With Carbapenem-Resistant Acinetobacter baumannii in Thailand Hospital?
por: Apisarnthanarak, Anucha, et al.
Publicado: (2016)

135. Clinical and Microbiologic Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia
por: Cho, Eunbeen, et al.
Publicado: (2019)

Epidemiological situation, laboratory capacity and preparedness for carbapenem-resistant Acinetobacter baumannii in Europe, 2019
por: Lötsch, Felix, et al.
Publicado: (2020)

642. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

Quantitative proteomics to study carbapenem resistance in Acinetobacter baumannii
por: Tiwari, Vishvanath, et al.
Publicado: (2014)

Fanny pack transmission of carbapenem-resistant Acinetobacter baumannii
por: DelleFave, Amber, et al.
Publicado: (2023)

581. The Epidemiology of Imipenem-Resistant Acinetobacter baumannii Bacteremia in a Pediatric Intensive Care Unit and Carbapenem Use
por: Kim, Dongsub, et al.
Publicado: (2019)

1111. Lack of Effectiveness of Colistin in Carbapenem-Resistant Acinetobacter baumannii : A Retrospective Single Center Cohort Study
por: Kim, Si-Ho, et al.
Publicado: (2023)

786. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) From 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

1006. Association of Development of Pneumonia and Virulence Gene Expression in Acinetobacter baumannii Isolated from Clinical Specimens
por: Bae, Ji Yun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ocq29sebt2fqj6u921tj0qthu